EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Failure patterns after definitive radiotherapy with elective neck irradiation ≤ 40 Gy for head and neck cancer: a multi-institutional study

Hideya Yamazaki, Gen Suzuki, Kei Yamada, Norihiro Aibe, Koji Masui, Takuya Kimoto, Shinsuke Nagasawa, Kanako Kawabata, Shoko Hirano, Satoshi Ikeda, Yuki Yoshino, Akito Asato, Tomoki Yamaguchi, Naohiro Kodani, Daisuke Shimizu, Satoaki Nakamura

Journal of Radiation Research · 2026-10-31

DOI: 10.1093/jrr/rrag093 ↗
AbstractBibliografische Angaben

Abstract

Abstract To evaluate the efficacy and patterns of failure after definitive radiotherapy (RT) using an elective nodal irradiation (ENI) dose of ≤40 Gy for head and neck cancer. We retrospectively analyzed 290 patients with stage I–IV oropharyngeal cancer (OPC), hypopharyngeal cancer (HPC), or laryngeal cancer (LYC) who underwent definitive RT with an ENI dose of ≤40 Gy at three institutions between 2008 and 2024. A total of 278 patients received 40 Gy of ENI, whereas ENI was omitted in 12 patients (ENI-omission). The study endpoints included patterns of failure, local control (LC), regional control (RC), progression-free survival (PFS) and overall survival (OS). With a median follow-up of 35 months among surviving patients, the 2-year LC, RC, PFS and OS rates were 79.8%, 91.2%, 63.1% and 79.8%, respectively. Regional recurrence within the ENI field occurred in only four patients (1.4%), including no patients in the ENI-omission group and four in the 40-Gy ENI group. Only one patient experienced an isolated ENI field recurrence. In the multivariable analysis, advanced N category, systemic therapy and prescribed dose were associated with OS. Advanced N category was also an independent predictor of both RC and PFS. Definitive RT using an ENI dose of ≤40 Gy achieved favorable oncologic outcomes with low incidence of regional recurrence within the ENI field. These findings support the feasibility of an ENI dose of ≤40 Gy while maintaining enough elective nodal control.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →